Avibactam activity against extended-spectrum AmpC β-lactamases

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1715-1716

  Porres Osante, Nerea ^a,b   Dupont, Hervé ^c,d   Torres, Carmen ^a,b   Ammenouche, Nacim ^c,d   de Champs, Christophe ^e,f   Mammeri, Hedi ^c,f  

^a UNIVERSITY OF LA RIOJA   (Spain)

^b CENTER FOR BIOMEDICAL RESEARCH OF LA RIOJA CIBIR   (Spain)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^e SERVICE DE DERMATOLOGIE   (France)

^f UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

Cephalosporins; Enterobacteria; Inhibitors; Resistance; Variants

Indexed keywords

AVIBACTAM; BETA LACTAMASE AMPC; CEFEPIME; CEFTAZIDIME; IMIPENEM; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; DRUG BINDING SITE; DRUG PROTEIN BINDING; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; HUMAN; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASES; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84903900875     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku002     Document Type: Letter

References (10)

1. Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012; 39: 86-9.
2. Stachyra T, Levasseur P, Péchereau MC et al. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 2009; 64: 326-9.
3. Livermore DM, Mushtaq S, Barker K et al. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline+avibactam (NXL104). J Antimicrob Chemother 2012; 67: 1354-8.
4. Lee SH, Jeong SH, Park YM. Characterization of blaCMY-10 a novel, plasmid-encoded AmpC-type β-lactamase gene in a clinical isolate of Enterobacter aerogenes. J Appl Microbiol 2003; 95: 744-52.
5. Nordmann P, Mammeri H. Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol 2007; 2: 297-307.
6. Guillon H, Tande D, Mammeri H. Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum β-lactamase AmpC. Antimicrob Agents Chemother 2011; 55: 4443-6.
7. Mammeri H, Poirel L, Fortineau N et al. Naturally occurring extended-spectrum cephalosporinases in Escherichia coli. Antimicrob Agents Chemother 2006; 50: 2573-6.
8. Mammeri H, Poirel L, Nordmann P. Extension of the hydrolysis spectrum of AmpC β-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix. J Antimicrob Chemother 2007; 60: 490-4.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI, Wayne, PA, USA, 2012.
10. Lahiri SD, Mangani S, Durand-Reville T et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases. Antimicrob Agents Chemother 2013; 57: 2496-505.